News | December 13, 2021
ICMR Dibrugarh designs kit to detect Omicron variant in two hours
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity
The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
An MoU was signed between B Medical Systems and Gujarat government recently
This is the fourth facility from the company to receive this registration
Subscribe To Our Newsletter & Stay Updated
